News - Gilenya


Current filters:


Popular Filters

1 to 25 of 28 results

AAN 2014: Novartis’ MS drug Gilenya slows brain volume loss


Data from Swiss drug major Novartis has shown that more patients with relapsing multiple sclerosis treated…

EuropeGilenyaHealthHealth Medical PharmaMedicineMSMultiple sclerosisNeurologicalNovartisPharmaceuticalResearch

Novartis MS drug Gilenya leads to reduction in brain volume drug

Novartis MS drug Gilenya leads to reduction in brain volume drug


Novartis has revealed new data indicating that continued treatment with Gilenya led to a reduction in…

CNS DiseasesEuropeGilenyaNovartisPharmaceuticalResearch

Mixed US views on Gilenya, Aubagio and Tecfidera as breakthrough MS drugs


More than half of surveyed neurologists consider US biotech firm Biogen Idec's (Nasdaq: BIIB) Tecfidera…

AubagioBiogen IdecGilenyaMarkets & MarketingNeurologicalNorth AmericaNovartisPharmaceuticalPricingSanofiTecfidera

FDA investigating rare brain infection in patient taking Gilenya


In a safety communication issued on Thursday (August 29), the US Food and Drug Administration is alerting…

GilenyaNeurologicalNorth AmericaNovartisPharmaceuticalRegulation

Multiple sclerosis market could reach $18.3 billion in 2018


The multiple sclerosis (MS) market is expected to peak at $18.3 billion in 2018, according to healthcare…

AubagioBiogen IdecFinancialGilenyaGlobalNovartisPharmaceuticalSanofiTecfidera

New data show Novartis' Gilenya benefited patients by improving all four key measures of RMS


Swiss drug major Novartis' (NOVN: VX) says that its blockbuster drug Gilenya (fingolimod), the first…


Multiple sclerosis drug fingolimod may one day treat colorectal cancer, say US researchers


After uncovering a mechanism that promotes chronic intestinal inflammation and the development of colorectal…


Highlights from ECTRIMS include new data for Gilenya, Sativex and Aubagio


New data presented at the 28th congress of the European Committee for Treatment and Research in Multiple…

AlmirallAubagioBiotechnologyGenzymeGilenyaGW PharmaceuticalsNeurologicalNovartisPharmaceuticalResearchSanofiSativex

Scotland denies access to Roche skin cancer drug Zelboraf, but OKs Novartis' Gilenya


Swiss drug major Roche (ROG SIX) says it is "extremely disappointed" that the Scottish Medicines Consortium…


EMA confirms positive benefit-risk profile for Novartis' Gilenya, but with label change; updated US label


Novartis said on Friday that the European Medicines Agency's Committee for Medicinal Products for Human…

EuropeGilenyaNeurologicalNorth AmericaNovartisPharmaceuticalRegulation

Novartis makes Tekturna label change, updates on Gilenya and stops alisporivir trial


In a day of mixed news for the Swiss drug major, Novartis (NOVN: VX) said yesterday that it has updated…


Positive NICE news for Gilenya for MS and Incivo for hep C


There was good news from the UK drugs watchdog the Institute for Health and Clinical Excellence (NICE)…

Anti-viralsEuropeGilenyaIncivoJanssen-CilagJohnson & JohnsonNeurologicalNovartisPharmaceuticalPricingRegulation

Germany’s IQWiG finds “hint” of advantage for Novartis’ Gilenya


The German Institute for Quality and Efficiency in Health Care (IQWiG) has assessed whether Swiss drug…


EMA starts review of Gilenya; guidance on biosimilar interferon beta


The European Medicines Agency has begun a review of the benefits and risks of Swiss drug major Novartis’…

BiotechnologyEuropeGenericsGilenyainterferon betaNeurologicalNovartisPharmaceuticalRegulation

Erbitux and Gilenya added to Australia’s PBS listing


More than 400,000 Australians will benefit from new subsidized medicines, effective September 1, as Minister…

Asia-PacificErbituxGilenyaMerck KGaANeurologicalNovartisOncologyPharmaceuticalPricingRegulation

1 to 25 of 28 results

Back to top